Display options
Cite
Tadayon F, Arezegar HR, Khorrami MH, et al. Evaluation of prostatic cancer prevalence in patients with prostatic-specific antigen between 4 and 10 and normal digital rectal examination. Adv Biomed Res. 2016;5:112doi: 10.4103/2277-9175.184298.
Tadayon, F., Arezegar, H. R., Khorrami, M. H., Hashemi Juzdani, R., Shahdoost, A. A., & Mellat, M. (2016). Evaluation of prostatic cancer prevalence in patients with prostatic-specific antigen between 4 and 10 and normal digital rectal examination. Advanced biomedical research, 5112. https://doi.org/10.4103/2277-9175.184298
Tadayon, Farhad, et al. "Evaluation of prostatic cancer prevalence in patients with prostatic-specific antigen between 4 and 10 and normal digital rectal examination." Advanced biomedical research vol. 5 (2016): 112. doi: https://doi.org/10.4103/2277-9175.184298
Tadayon F, Arezegar HR, Khorrami MH, Hashemi Juzdani R, Shahdoost AA, Mellat M. Evaluation of prostatic cancer prevalence in patients with prostatic-specific antigen between 4 and 10 and normal digital rectal examination. Adv Biomed Res. 2016 Jun 20;5:112. doi: 10.4103/2277-9175.184298. eCollection 2016. PMID: 27403407; PMCID: PMC4926539.
Copy Download .nbib Format: NLM
Share it on

Adv Biomed Res. 2016 Jun 20;5:112. doi: 10.4103/2277-9175.184298. eCollection 2016.

Evaluation of prostatic cancer prevalence in patients with prostatic-specific antigen between 4 and 10 and normal digital rectal examination.

Advanced biomedical research

Farhad Tadayon, Hamid Reza Arezegar, Mohammad Hatef Khorrami, Rasoul Hashemi Juzdani, Amir Abbas Shahdoost, Mehdi Mellat

Affiliations

  1. Department of Urology, Isfahan University of Medical Science, Isfahan, Iran.

PMID: 27403407 PMCID: PMC4926539 DOI: 10.4103/2277-9175.184298

Abstract

BACKGROUND: Prostate cancer is one of the most common male cancers. The prevalence of prostate cancer is different due to genetic and environmental factors. Diagnosis of prostate cancer is by biopsy due to prostate-specific antigen (PSA) and Digital Rectal Examination (DRE). Controversy about decision making for prostate biopsy in PSA between 4 and 10 and normal DRE, is one of the problems in this time. In this study we evaluated the prevalence of prostate cancer in males with PSA between 4 and 10 and normal DRE. We also evaluated the PSA density and percent of free PSA in patients with prostate cancer.

MATERIALS AND METHODS: A total of 121 males with PSA between 4 and 10 and normal DRE, were evaluated. Then, transrectal ultrasonography (TRUS) andprostate biopsy from 12 points of peripheral zone, was done. These data were analyzed by Chi-square, t-test and ANOVA and Roc curve.

RESULTS: In this study, the prevalence of prostate cancer in PSA between 4 and 10 and normal DRE, was evaluated, 29.8%. With use of Roc curve, PSA density cutoff point was calculated 0.12 and percent of free PSA cutoff point, was calculated, 18%.

CONCLUSION: In males with PSA between 4 and 10 and normal DRE, PSA density smaller than 0.12-0.15, and percent of free PSA greater than 18%, the prevalence of prostate cancer is very few and we can safely ignore the TRUS and prostate biopsy in these males and eliminate its costs and side effects.

Keywords: Benign prostatic hyperplasia; digital rectal examination; percentage of free prostate-specific antigen; prostate cancer; prostate-specific antigen; prostate-specific antigen density

References

  1. Int Braz J Urol. 2009 Sep-Oct;35(5):551-5; discussion 555-8 - PubMed
  2. JAMA. 1998 May 20;279(19):1542-7 - PubMed
  3. Eur Urol. 2001 May;39(5):538-43 - PubMed
  4. Br J Urol. 1998 Sep;82(3):393-7 - PubMed
  5. Onkologie. 2001 Feb;24(1):33-7 - PubMed
  6. JAMA. 1997 May 14;277(18):1445-51 - PubMed
  7. Am J Clin Oncol. 2001 Dec;24(6):610-3 - PubMed
  8. Curr Urol Rep. 2000 May;1(1):78-82 - PubMed

Publication Types